Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
Acadia becomes the latest to fall foul of the US FDA's apparently increasingly strict stance.
Just when investors thought they had seen the worst of it, the delayed Fibrogen/Astrazeneca project faces another problem.
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.
Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.